Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Reviva Pharmaceuticals Holdings Inc (RVPHW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RVPHW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -25.07% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.81M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.11 | 52 Weeks Range 0.02 - 0.52 | Updated Date 05/26/2025 |
52 Weeks Range 0.02 - 0.52 | Updated Date 05/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -178.72% | Return on Equity (TTM) -916.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 40777801 |
Shares Outstanding - | Shares Floating 40777801 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Reviva Pharmaceuticals Holdings Inc
Company Overview
History and Background
Reviva Pharmaceuticals Holdings Inc. is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) diseases. Founded in 2006, it has focused on developing new chemical entities for unmet medical needs.
Core Business Areas
- Drug Development: Focuses on research and development of new chemical entities for CNS disorders.
Leadership and Structure
The leadership team includes key executives in research, development, and management. The company operates with a structure typical of a clinical-stage biopharmaceutical firm.
Top Products and Market Share
Key Offerings
- Bucinazine (RP5063): A dopamine D2/serotonin 2A receptor modulator in Phase 3 clinical trials for schizophrenia. Market share is currently 0% as it's not yet approved. Competitors include antipsychotics from companies like Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), and Eli Lilly (LLY).
- RP5063 for Pulmonary Arterial Hypertension: An indication that is currently being investigated in Phase 2 clinical trials. Market share is currently 0% as it's not yet approved. Competitors include drugs from companies such as United Therapeutics (UTHR) and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The pharmaceutical industry is dynamic, driven by innovation, regulatory changes, and evolving healthcare needs. The CNS market is significant, with increasing demand for novel treatments for neurological and psychiatric disorders.
Positioning
Reviva is positioned as an innovator developing new chemical entities, targeting unmet needs in CNS disorders. Its competitive advantage lies in its novel mechanism of action.
Total Addressable Market (TAM)
The global schizophrenia market and PAH market are multibillion-dollar markets. Reviva's RP5063, if approved, could capture a portion of these markets. TAM for Schizophrenia is estimated at $8.6 Billion in 2024.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Targeting unmet medical needs
- Experienced management team
- Phase 3 clinical trial progress for bucinazine
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- No currently marketed products
- Small company scale
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory approvals
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Market access challenges
Competitors and Market Share
Key Competitors
- LLY
- JNJ
- TEVA
- UTHR
Competitive Landscape
Reviva operates in a competitive pharmaceutical landscape dominated by larger, well-established companies. Its competitive advantage relies on its novel compounds and targeting specific unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement of clinical trial programs rather than revenue growth.
Future Projections: Future growth is dependent on positive clinical trial results, regulatory approvals, and successful commercialization.
Recent Initiatives: Focusing on advancing RP5063 through Phase 3 clinical trials for schizophrenia and Phase 2 for PAH.
Summary
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company with promising drug candidates. Its success hinges on the outcome of clinical trials, especially for Bucinazine in schizophrenia. The company faces challenges in funding and competition from larger pharmaceutical entities. Positive trial results and strategic partnerships are crucial for its future growth. Its focus on novel mechanisms and unmet needs provides some differentiation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share figures are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Reviva Pharmaceuticals Holdings Inc
Exchange NASDAQ | Headquaters Cupertino, CA, United States | ||
IPO Launch date 2018-10-18 | Founder, CEO, President & Director Dr. Laxminarayan Bhat Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.revivapharma.com |
Full time employees 14 | Website https://www.revivapharma.com | ||
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.